Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Understanding Alzheimer's Disease Heterogeneity by Investigating Interplay Between Amyloid Beta Strains and Alpha-Synuclein Co-Pathology

FY 2023-24

Summary
The lived experience people have with Alzheimer's Disease will differ from person to person. Some people with Alzheimer's Disease may have a very quick decline, while others may have a slow decline. The exact reason for this variability in Alzheimer's Disease is unknown. Alzheimer's Disease is thought to be caused by the buildup of a protein in the brain called Amyloid Beta. I believe that different variants of the Amyloid Beta buildup may contribute to the variability observed in people with Alzheimer's Disease. Specifically, I believe only some variants of Amyloid Beta buildup will trigger the buildup of another protein called Alpha Synuclein. Alpha Synuclein buildup alone is known to cause other diseases and is often seen in some people with Alzheimer's Disease, potentially worsening and speeding up the progression of the disease. To test if specific variants of Amyloid Beta buildup will in turn cause Alpha Synuclein buildup, I will use mice that have both human Amyloid Beta and Alpha Synuclein in their brains. By having the mice develop specific variants of Amyloid Beta, I can test the memory and the amount of Alpha Synuclein buildup in the sick mice and compare them between the variants of Amyloid Beta. This can test my hypothesis that specific variants of Amyloid Beta buildup will cause variability in Alzheimer's Diseases by effecting the amount of Alpha Synuclein that is developed. For my hypothesis to be true, I expect one variant of Amyloid Beta buildup will cause more Alpha Synuclein to develop than the other, and these mice that develop more Alpha Synuclein buildup will have worse memory. This project will help researchers understand the root cause for the variability in the lived experience of those with Alzheimer's Disease. This improved understanding can then be used to develop treatments that target the specific variant of protein buildup the person has, which may provide greater benefits than the current "one-drug-fits-all" approach.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
496589
Name
Silver Nicholas R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Understanding Alzheimer's Disease Heterogeneity by Investigating Interplay Between Amyloid Beta Strains and Alpha-Synuclein Co-Pathology
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Alpha Synuclein; Alzheimer'S Disease; Amyloid Beta; Protein Aggregate Strains; Protein Aggregates
Abstract
The lived experience people have with Alzheimer's Disease will differ from person to person. Some people with Alzheimer's Disease may have a very quick decline, while others may have a slow decline. The exact reason for this variability in Alzheimer's Disease is unknown. Alzheimer's Disease is thought to be caused by the buildup of a protein in the brain called Amyloid Beta. I believe that different variants of the Amyloid Beta buildup may contribute to the variability observed in people with Alzheimer's Disease. Specifically, I believe only some variants of Amyloid Beta buildup will trigger the buildup of another protein called Alpha Synuclein. Alpha Synuclein buildup alone is known to cause other diseases and is often seen in some people with Alzheimer's Disease, potentially worsening and speeding up the progression of the disease. To test if specific variants of Amyloid Beta buildup will in turn cause Alpha Synuclein buildup, I will use mice that have both human Amyloid Beta and Alpha Synuclein in their brains. By having the mice develop specific variants of Amyloid Beta, I can test the memory and the amount of Alpha Synuclein buildup in the sick mice and compare them between the variants of Amyloid Beta. This can test my hypothesis that specific variants of Amyloid Beta buildup will cause variability in Alzheimer's Diseases by effecting the amount of Alpha Synuclein that is developed. For my hypothesis to be true, I expect one variant of Amyloid Beta buildup will cause more Alpha Synuclein to develop than the other, and these mice that develop more Alpha Synuclein buildup will have worse memory. This project will help researchers understand the root cause for the variability in the lived experience of those with Alzheimer's Disease. This improved understanding can then be used to develop treatments that target the specific variant of protein buildup the person has, which may provide greater benefits than the current "one-drug-fits-all" approach.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Silver, Nicholas R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~